Summary & Overview

Inflammatory Bowel Disease without CC/MCC: Inpatient Reimbursement Overview

DRG 387 encompasses inpatient admissions for inflammatory bowel disease without Complication or Comorbidity or Major Complication or Comorbidity, focusing on baseline medical or surgical management. Correct assignment affects Medicare payment because the Diagnosis-Related Group determines the hospital’s bundled reimbursement for the stay.

DRG Inflammatory Bowel Disease without CC/MCCDRG 387Inflammatory Bowel DiseaseDiagnosis-Related GroupInpatient ReimbursementMedicareGastroenterologyColorectal Surgery

DRG 387 Overview

DRG 387 covers inpatient hospital admissions for inflammatory bowel disease without Complication or Comorbidity and without Major Complication or Comorbidity, typically including cases of ulcerative colitis or Crohn disease managed without significant additional diagnoses. This Diagnosis-Related Group groups patients with similar clinical resource needs for Medicare payment purposes. It matters for Medicare payment because the grouped assignment drives the bundled reimbursement amount for the hospital stay. Accurate documentation of the primary diagnosis and any comorbid conditions determines whether a case belongs in this category.

Clinical Trials

Hospital-based acute management trials of moderate to severe inflammatory bowel disease flares focusing on short-term corticosteroid-sparing strategies and rapid induction regimens. These studies enroll adult inpatients admitted with ulcerative colitis or Crohn’s disease experiencing active flares that do not meet CC/MCC severity thresholds, testing interventions intended to achieve clinical remission within days to weeks and minimize length of stay. Results inform hospital clinicians about effective acute care algorithms and inform payers about interventions that may reduce inpatient resource use and readmission risk.
Comparative effectiveness studies evaluating medical versus early minimally invasive surgical approaches for localized complications (such as medically refractory colitis segments or limited strictures) in non–critically ill patients. These trials compare outcomes like time to return of bowel function, complication rates, discharge disposition, and 30–90 day healthcare utilization among patients appropriate for either approach, often stratifying by disease phenotype and prior outpatient therapy. Findings guide providers in selecting inpatient care paths that balance short-term clinical benefit, complication avoidance, and downstream costs relevant to reimbursement and DRG grouping.
Post-discharge outcomes and transitional care trials testing structured discharge planning, outpatient infusion/appointment scheduling, and remote monitoring to prevent readmissions for patients hospitalized with inflammatory bowel disease. These pragmatic studies enroll patients discharged after an index inpatient stay without major complications and measure readmission rates, outpatient visit adherence, patient-reported disease control, and total 30–90 day costs. Evidence from these studies is crucial for providers and payers focused on reducing avoidable readmissions within the DRG, optimizing post-acute resource allocation, and improving value-based outcomes.

Hospital-based acute management trials of moderate to severe inflammatory bowel disease flares focusing on short-term corticosteroid-sparing strategies and rapid induction regimens. These studies enroll adult inpatients admitted with ulcerative colitis or Crohn’s disease experiencing active flares that do not meet CC/MCC severity thresholds, testing interventions intended to achieve clinical remission within days to weeks and minimize length of stay. Results inform hospital clinicians about effective acute care algorithms and inform payers about interventions that may reduce inpatient resource use and readmission risk.
Comparative effectiveness studies evaluating medical versus early minimally invasive surgical approaches for localized complications (such as medically refractory colitis segments or limited strictures) in non–critically ill patients. These trials compare outcomes like time to return of bowel function, complication rates, discharge disposition, and 30–90 day healthcare utilization among patients appropriate for either approach, often stratifying by disease phenotype and prior outpatient therapy. Findings guide providers in selecting inpatient care paths that balance short-term clinical benefit, complication avoidance, and downstream costs relevant to reimbursement and DRG grouping.
Post-discharge outcomes and transitional care trials testing structured discharge planning, outpatient infusion/appointment scheduling, and remote monitoring to prevent readmissions for patients hospitalized with inflammatory bowel disease. These pragmatic studies enroll patients discharged after an index inpatient stay without major complications and measure readmission rates, outpatient visit adherence, patient-reported disease control, and total 30–90 day costs. Evidence from these studies is crucial for providers and payers focused on reducing avoidable readmissions within the DRG, optimizing post-acute resource allocation, and improving value-based outcomes.

OpenPayer

Summary & Overview

Inflammatory Bowel Disease without CC/MCC: Inpatient Reimbursement Overview

DRG 387 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes